Novel Cytisine (cas 15191-27-2) derivatives exert anti-liver fibrosis effect via PI3K/Akt/Smad pathway

Add time:07/29/2019    Source:sciencedirect.com

A series of new Cytisine (cas 15191-27-2) derivatives with a unique endocyclic scaffold were synthesized and evaluated for their inhibitory effect on collagen α1 (I) (COL1A1) promotor in human LX2 cells, taking cytisine as the lead. Structure-activity relationship (SAR) revealed that introducing a 12N-benzyl substitution might significantly enhance the activity. Compound 5f exhibited a promising inhibitory potency against COL1A1 with an IC50 value of 12.8 μM in human LX2 cells, and an inspiring inhibition activity against COL1A1 on both mRNA and protein levels. It also effectively inhibited the expression of α smooth muscle actin (α-SMA), connective tissue growth factor (CTGA), matrix metalloprotein 2 (MMP-2), and transforming growth factor β1 (TGFβ1), indicating an extensive inhibitory effect against fibrogenetic proteins. In addition, compound 5f displayed reasonable PK and safety profiles. The primary mechanism study indicated that it might repress the hepatic fibrogenesis via PI3K/Akt/Smad signaling pathway. The results provided powerful information for further structure optimization, and compound 5f was selected as a novel anti-liver fibrosis agent for further investigation.

We also recommend Trading Suppliers and Manufacturers of Cytisine (cas 15191-27-2). Pls Click Website Link as below: cas 15191-27-2 suppliers

Prev:Efficient synthesis of tetrazole derivatives of Cytisine (cas 15191-27-2) using the azido-Ugi reaction
Next:Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine (cas 15191-27-2))